Halozyme Therapeutics, Inc. (LON:0J2O)
63.16
+1.48 (2.41%)
At close: Aug 8, 2025
Halozyme Therapeutics Employees
Halozyme Therapeutics had 350 employees as of December 31, 2024. The number of employees decreased by 23 or -6.17% compared to the previous year.
Employees
350
Change (1Y)
-23
Growth (1Y)
-6.17%
Revenue / Employee
$2,458,036
Profits / Employee
$1,162,163
Market Cap
5.47B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 350 | -23 | -6.17% |
Dec 31, 2023 | 373 | -20 | -5.09% |
Dec 31, 2022 | 393 | 248 | 171.03% |
Dec 31, 2021 | 145 | 9 | 6.62% |
Dec 31, 2020 | 136 | 4 | 3.03% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
Oxford Nanopore Technologies | 1,382 |
HUTCHMED (China) | 1,811 |
Halozyme Therapeutics News
- 18 days ago - European Commission Approved DARZALEX Faspro® for Adult Patients with Smouldering Multiple Myeloma - PRNewsWire
- 20 days ago - Halozyme to Report Second Quarter 2025 Financial and Operating Results - PRNewsWire
- 27 days ago - Halozyme: Is Robust Growth Masking A Long-Term Value Trap? (Rating Downgrade) - Seeking Alpha
- 5 weeks ago - Halozyme Therapeutics Added to Russell 1000® Index - PRNewsWire
- 7 weeks ago - Halozyme Announces argenx Received European Commission Approval for VYVGART® Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) - PRNewsWire
- 2 months ago - Halozyme Therapeutics: The Waters Become Muddled - Seeking Alpha
- 2 months ago - Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today - Benzinga
- 2 months ago - Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years - Benzinga